Voyager Acquisition Corp/cayman Islands 8-K filings

Veraxa Biotech Holding AG has entered into a securities purchase agreement for a $27.5 million senior secured note and a $50 million share purchase agreement with Lincoln Park Capital Fund, bolstering its financial position.

Voyager Acquisition Corp. shareholders approved the business combination with Veraxa Biotech AG, despite a high redemption rate of 99.67% of Class A shares.

VERAXA Biotech AG shareholders have approved the merger with Voyager Acquisition Corp. and the issuance of new shares, moving closer to a NASDAQ listing under the symbol VRXA.

Voyager Acquisition Corp. amended its business combination agreement with Veraxa Biotech AG, increasing the merger consideration to $1.35 billion and adjusting sponsor equity.

Voyager Acquisition Corp. and Veraxa Biotech AG have amended their business combination agreement, extending the merger deadline to August 7, 2026, and modifying termination fee provisions.

Voyager Acquisition Corp. announced a definitive business combination agreement with Veraxa Biotech AG, a Swiss oncology company, valuing the combined entity at approximately $1.3 billion.

Voyager Acquisition Corp. and Veraxa Biotech AG have formalized the participation of Veraxa Biotech Holding AG (PubCo) and Veraxa Cayman Merger Sub in their previously announced business combination agreement.

Voyager Acquisition Corp. and Veraxa Biotech AG have announced a definitive business combination agreement, valuing Veraxa at $1.3 billion, to create a Nasdaq-listed biopharmaceutical company focused on next-generation cancer therapies.

Voyager Acquisition Corp. successfully closed its initial public offering, raising $253 million through the sale of units, each consisting of one Class A ordinary share and one-half of one warrant.

Voyager Acquisition Corp. has formalized its warrant agreement and successfully closed its initial public offering, raising $253 million.